Cancer – ENCIT-01: Engineered Neuroblastoma Cellular Immunotherapy
What is the goal of this study?
ENCIT-01 is a phase 1 trial. Through this study, researchers are working to answer these questions:
- Is T-cell therapy safe to give to children and young adults with recurrent or refractory neuroblastoma?
- What is the largest dose that children and young adults can stand (the maximum tolerated dose)?
- Does T-cell therapy work against neuroblastoma?
Who can join the study?
This study might be a good fit for children and young adults who:
- Are 1 to 18 years old
- Have high-risk neuroblastoma and have responded poorly to standard treatments (chemotherapy, radiation therapy or both)
- Have had their neuroblastoma come back (a recurrence) after treatment
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
What will happen if my child takes part in this study?
You can read about the ENCIT-01 study protocol on clinicaltrials.gov.